InfraReDx Showcases LipiScan™ Coronary Imaging System for Identification of Lipid Core Plaque at LUMEN 2010
InfraReDx, Inc., developer of novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues exhibited at LUMEN 2010, the world's premier ST-elevation myocardial infarction (STEMI) meeting, held February 25-27, 2010 at the Loews Miami Beach Hotel in Miami Beach, Florida. The 9th Annual LUMEN meeting is an educational symposium providing updates from world-renowned experts in key areas of interventional cardiology and vascular intervention.
InfraReDx’s LipiScan near-infrared (NIR) spectroscopy catheter is the only FDA-cleared product to detect and assess the intracoronary composition of lipid core plaque, which cannot be detected by commonly used diagnostic tests such as treadmill exams and coronary angiograms. Lipid core-containing plaque (LCP) is believed to be vulnerable plaque. LCP is widely considered to be responsible for a significant number of stenting procedure complications and is believed to be the primary cause of acute coronary events, the leading cause of death in the developed world.
In addition to its presence at LUMEN 2010, InfraReDx was an active speaking and panel participant during the recent Cardiovascular Research Technologies (CRT) annual meeting in Washington, D.C., and live case demonstrations of the LipiScan system were a highlight of the Scottsdale Interventional Forum in Scottsdale, Arizona, earlier this month. InfraReDx will continue to showcase LipiScan at upcoming events and medical meetings, including the 59th Annual Scientific Sessions of the American College of Cardiology (ACC) in Atlanta.
InfraReDx, Inc., headquartered in Burlington, Massachusetts, is a privately-funded medical device company founded in 1998 and focused on intravascular characterization of disease in the coronary arteries. InfraReDx is the maker of the LipiScan™ system, a novel near-infrared (NIR) spectroscopy catheter that can detect the lipid core coronary plaques suspected to cause most heart attacks and known to complicate stenting procedures. For more information, visit: http://www.infraredx.com
